Expression of galectin-3 in adenoid cystic carcinoma & mucoepidermoid carcinoma of salivary glands- a study from Pakistan

 
 
 
  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract


    Background: Adenoid cystic carcinoma (AdCC) and mucoepidermoid carcinoma (MEC) are the commonest salivary gland malignancies in Pakistan constituting almost 75% of all malignant salivary gland tumours.

    Objective: The objective of this study was to determine the expression of galectin-3 (Gal-3) in AdCC and MEC of salivary glands and to see its relationship with histological differentiation in these tumours.

    Method: This descriptive study was conducted at the Department of Morbid Anatomy and Histopathology/ Oral Pathology, University of Health Sciences Lahore, Pakistan. Biopsies and detailed clinical data of 20 cases each of adenoid cystic carcinoma and mucoepidermoid carcinoma reported at local tertiary care hospitals from Jan. 2014 to Sep. 2015 were retrieved. The histologic diagnosis was made on Hematoxylin and Eosin staining. The tumours were graded into grades I, II & III according to the most recent grading criteria. AdCC was studied with respect to its morphological patterns (tubular, cribriform and solid) while MEC was studied with special concern to the cell types seen in it (mucous, intermediate, squamous and clear cells). Immunohistochemical expression of galectin-3 was determined in these tumours with respect to histological grades, patterns and cell types seen.

    Results: Moderate positivity (55%) for anti-galectin-3 antibody was the most frequently observed score for galectin-3 in both MEC and AdCC. Moderate positive (55%) staining reaction was followed by weak positive (30%) staining reaction in AdCC. Total score for antigalectin-3 antibody, positive stromal reaction (intensity) and location of cellular signals for anti-galectin-3 antibody were all found to be significantly associated with grades of AdCC. Also, histological pattern of AdCC (tubular, cribriform and solid) were significantly associated with type of anti-galectin-3 staining pattern of cells (p<0.001). In MEC, moderate positive (55%) staining for anti-galectin-3 antibody was followed by strong positive reaction (30%). The total score for anti-galectin-3 antibody was significantly associated with grades of the tumour and lymph node status. Also, the type of staining reaction in cells was significantly associated with cell type (mucous, squamous and intermediate cells).

    Conclusion: It can be concluded from the current study that expression of Gal-3 decreases with decreasing differentiation in parenchyma of malignant tumours while its expression in tumour extracellular environment increases with increasing grade of the tumour.Also, it can be concluded that nuclear expression of Gal-3 is associated tumour differentiation and cytoplasmic expression with tumour cell proliferation.


  • Keywords


    Adenoid Cystic Carcinoma; Galectin-3; Mucoepidermoid Carcinoma

  • References


      [1] Long-jiang L, Yi L, Yu-ming W, Hua L & Hong-wei Z (2008) Clinical analysis of salivary gland tumour cases in West China in past 50 years. Oral Oncology 44, 187-192. https://doi.org/10.1016/j.oraloncology.2007.01.016.

      [2] Kızıl Y, Aydil U, Ekinci O, Dilci A, Köybaşюğlu A, Düzlü M & Ĭnal E (2013) Salivary Gland Tumors in Turkey: Demographic Features and Histopathological Distribution of 510 Patients. Indian Journal of Otolaryngology and Head and Neck Surgery 65,112–20. https://doi.org/10.1007/s12070-012-0594-6.

      [3] Ettl T, Schwarz-Furlan S, Gosau M & Reichert TE (2012) Salivary gland carcinomas. Oral and maxillofacial surgery 16, 267–283. https://doi.org/10.1007/s10006-012-0350-9.

      [4] Vuhahula EAM (2004) Salivary gland tumors in Uganda: clinical pathological study. African Health Sciences 4, 15-23. PMID: 15126188.

      [5] Gondivkar SM, Gadbail AR, Chole R & Parikh RV (2011). Adenoid cystic carcinoma: A rare clinical entity and literature review. Oral Oncology 47, 231-236.https://doi.org/10.1016/j.oraloncology.2011.01.009.

      [6] Bradley PJ (2004) Adenoid cystic carcinoma of the head and neck: a review. Current Opinion Otolaryngology & Head and Neck Surgery 12, 127–32. PMID: 15167050 https://doi.org/10.1097/00020840-200404000-00013.

      [7] Kolay SK, Sinha RK, Singh NN & Parwani R (2014) Adenoid cystic carcinoma of the palate and tongue: Report of two cases. SRM Journal of Research in Dental Sciences 5(3), 195-198. https://doi.org/10.4103/0976-433X.138756.

      [8] Wang YL, Zhu YX, Chen TZ, Wang Y, Sun GH, Zhang L, Huang CP, Wang ZY, Shen Q, Li DS, Yi W & Ji QH (2012) Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: Experience of one cancer center 1997–2007. Acta Oto-Laryngologica 132, 879-886. https://doi.org/10.3109/00016489.2012.662715.

      [9] Singla N, Rathod G & Singla D (2015) Adenoid cystic carcinoma of the parotid gland - A case report and review of literature. International Archives of Integrated Medicine 2(4), 182-186. ISSN: 2394-0026 (P).

      [10] Ozawa H, Tomita K, Sakamoto K, Tagawa T, Fujii R, Kanzaki S, Ogawa1 K, Kameyama K & Fujii M (2008) Mucoepidermoid Carcinoma of the Head and Neck: Clinical Analysis of 43 Patients. Japanese Journal of Clinical Oncology 38(6), 414-418.https://doi.org/10.1093/jjco/hyn045.

      [11] Eveson JW, Reichart P & Sidransky D (2005) World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. In: Tumours of the Salivary Glands. Lyon: IARC Press; pp. 219-222.

      [12] Adesina OA, Nggada HA, James O, Olasoji HO, Adesina OO & Kaumi AM (2012) Mucoepidermoid carcinoma of the submandibular gland in a 6yr old boy. Pakistan Oral & Dental Journal 32(2), 210-213.

      [13] Luna MA (2006) Salivary Mucoepidermoid Carcinoma: Revisited. Advances in Anatomic Pathology 13, 293–307. https://doi.org/10.1097/01.pap.0000213058.74509.d3.

      [14] Ranganath MK, Matmari V, Narayanaswamy UD & Balve RM (2011) Mucoepidermoid carcinoma presenting as a retromolar mucocele. Annals of Maxillofacial Surgery 1(1), 66–69.https://doi.org/10.4103/2231-0746.83161.

      [15] Costa AF, Gomes AM, Kozlowski EO, Stelling MP & Pavao MSG (2014). Extracellular galectin-3 in tumor progression and metastasis. Frontiers in Oncology 4(138), 1-9.https://doi.org/10.3389/fonc.2014.00138.

      [16] Dumic J, Dabelic S & Flögel,M (2006). Galectin-3: an open-ended story. Biochimica etBiophysica Acta 1760(4), 616–35 https://doi.org/10.1016/j.bbagen.2005.12.020.

      [17] Newlaczyl AU & Yu LG (2011). Galectin-3 – A jack-of-all-trades in cancer. Cancer letters 313(2), 123-128. https://doi.org/10.1016/j.canlet.2011.09.003.

      [18] Califice S, Castronovo V, Bracke M & Brûle FV (2004). Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 Vs tumor promotion of cytoplasmic galectin-3. Oncogene 23(45), 7527–7536. https://doi.org/10.1038/sj.onc.1207997.

      [19] Elad-Sfadia G, Haklai R, Balan E & Kloog Y (2004). Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. The Journal of Biological Chemistry 279(33), 34922–30. https://doi.org/10.1074/jbc.M312697200.

      [20] Yang RY, Rabinovich GA & Liu FT (2008). Galectins: structure, function and therapeutic potential. Expert Reviews in Molecular Medicine 10, 1-24. https://doi.org/10.1017/S1462399408000719.

      [21] Song L, Tang JW, Owusu L, Sun MZ, Wu J & Zhang J (2014). Galectin-3 in cancer. Clinica Chimica Acta., 431(1):185-191. https://doi.org/10.1016/j.cca.2014.01.019.

      [22] Teymoortash A, Pientka A, Schrader C, Tiemann M & Werner JA (2006). Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. Journal of Cancer Research and Clinical Oncology 132(1),51–56 https://doi.org/10.1007/s00432-005-0040-1.

      [23] Spiro RH, Huvos AG & Strong EW (1974). Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. American Journal of Surgery 128(4), 512-20 PMID: 4371368.https://doi.org/10.1016/0002-9610(74)90265-7.

      [24] Auclair, P.L., Goode, R.K., and Ellis, G.L., 1992. Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. Cancer, 69(8):2021–2030. DOI: 10.1002/1097-0142(19920415)69:8<2021: AID-CNCR2820690803>3.0.CO; 2-7.

      [25] Remmelink M, de Leval L, Decaestecker C, Duray A, Crompot E, Sirtaine N, Andre´ S, Kaltner H, Leroy X, Gabius HJ & Saussez S (2011). Quantitative immunohistochemical fingerprinting of adhesion/growth-regulatory galectins in salivary gland tumours: divergent profiles with diagnostic potential. Histopathology, 58: 543–56. https://doi.org/10.1111/j.1365-2559.2011.03776.x.

      [26] Arfaoui-Toumi A, Kria-Ben Mahmoud L, Ben Hmida M, Khalfallah MT, Regaya-Mzabi S, Bouraoui S (2010). Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian patients). Bull Cancer 97(2), 1-8. doi: 10.1684/bdc.2010.1032.

      [27] Huang ZL & Liu HY (2008). Expression of galectin-3 in liver metastasis of colon cancer and the inhibitory effect of modified citrus pectin. Nan Fang Yi Ke Da Xue Xue Bao= Journal of Southern Medical University 28(8), 1358-61. PMID: 18753060.

      [28] Wu ZH & Gan L (2007) Association of galectin-3 and E-cadherin expressions with lymph node metastasis of colon cancer. Nan Fang Yi Ke Da Xue Xue Bao= Journal of Southern Medical University 27(11), 1731-33. PMID: 18024302.

      [29] Okada K, Shimura T, Suehiro T, Mochiki E & Kuwano H (2006)Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Research. 26(2B):1369-76.PMID: 16619546.

      [30] El-Nagdy SY, Salama NM & Mourad MI (2013) Immunohistochemical clue for the histological overlap of salivary adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Interventional Medicine & Applied Science 5(3), 131–139 https://doi.org/10.1556/IMAS.5.2013.3.6.

      [31] Ferrazzo KL, Alves SR, Santos E, Martins MT & de Sousa SM (2007) Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. Oral Oncology 43(6), 580–585.doi:10.1016/j,oraloncology.2006.06.010.

      [32] Xu XC, Gallego JJS, Lotan R & El-Naggar AK (2000) Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms. International Journal ofOncology17(2),271–76. https://doi.org/10.3892/ijo.17.2.271.

      [33] Piantelli M, Iacobelli S, Almadori G,Iezzi M, Tinari N, Natoli C, Gabriella CG, Lauriola L & Ranelletti FO (2002) Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. Journal of Clinical Oncology 20(18), 3850-56.https://doi.org/10.1200/JCO.2002.01.078.

      [34] Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V & Raz A (2010) Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. International Journal of Cancer 127(11), 2530-41.https://doi.org/10.1002/ijc.25254.

      [35] Argüeso P & Panjwani N (2011). Focus on molecules: Galectin-3. Experimental Eye Research 92(1), 2-3.https://doi.org/10.1016/j.exer.2010.11.009.


 

View

Download

Article ID: 7197
 
DOI: 10.14419/ijdr.v5i1.7197




Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.